Brief: Simcere Pharmaceutical Sees Rev Of RMB3,349 Million To RMB3,409 Million For Six Months
July 27 (Reuters) - Simcere Pharmaceutical 2096.HK :
* SEES REVENUE OF APPROXIMATELY RMB3,349 MILLION TO RMB3,409
MILLION FOR SIX MONTHS
* SEES PROFIT ATTRIBUTABLE OF RMB2,245 MILLION TO RMB2,305
MILLION
FOR SIX MONTHS
* EXPECTED CHANGE IN PROFIT ATTRIBUTABLE ON NEGATIVE IMPACT
ON
COMPANY'S GROSS PROFIT MARGIN IN FIRST HALF, AMONG OTHERS
Further company coverage: 2096.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Simcere Pharmaceutical
See all newsBrief: Simcere Pharmaceutical Announces Approval For Marketing Of Yingmule In China By NMPA
Simcere Pharmaceutical jumps most in two months on Roche tie-up
Roche signs global licensing pact for Simcere's experimental blood cancer drug (updated)
Roche signs global licensing pact for Simcere's B-cell cancer drug candidate
Brief: Simcere Pharmaceutical Enters Exclusive Global Licensing Agreement With Roche For SIM0660